DOPASCAN Injection ([{sup 123}I]{beta}-CIT): A radiopharmaceutical with potential for the diagnosis of Parkinson's disease
Journal Article
·
· AIP Conference Proceedings
- Guilford Pharmaceuticals Inc., 6611 Tributary Street, Baltimore, Maryland 21224 (United States)
In conjunction with single photon emission computerized tomography (SPECT), the radiopharmaceutical [{sup 123}I]{beta}-CIT (DOPASCAN Injection) has demonstrated significant potential for the early diagnosis and monitoring of Parkinson's Disease. Well over 2000 patients worldwide have been studied with this product, which has completed phase II clinical studies. This review summarizes the development and clinical application of this new radiopharmaceutical product.
- OSTI ID:
- 21208098
- Journal Information:
- AIP Conference Proceedings, Journal Name: AIP Conference Proceedings Journal Issue: 1 Vol. 475; ISSN APCPCS; ISSN 0094-243X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Differential diagnosis of bilateral parietal abnormalities in I-123 IMP SPECT imaging
I-123 - FP-CIT pharmacokinetics and dosimetry show great potential for the evaluation of dopamine transporter system in clinical routine
Parametrization of textural patterns in {sup 123}I-ioflupane imaging for the automatic detection of Parkinsonism
Journal Article
·
Fri Nov 30 23:00:00 EST 1990
· Clinical Nuclear Medicine; (USA)
·
OSTI ID:6059670
I-123 - FP-CIT pharmacokinetics and dosimetry show great potential for the evaluation of dopamine transporter system in clinical routine
Journal Article
·
Wed May 01 00:00:00 EDT 1996
· Journal of Nuclear Medicine
·
OSTI ID:447764
Parametrization of textural patterns in {sup 123}I-ioflupane imaging for the automatic detection of Parkinsonism
Journal Article
·
Tue Jan 14 23:00:00 EST 2014
· Medical Physics
·
OSTI ID:22251245